BARDA backs GSK antibiotic with $94M in R&D support

The U.S. government's bioterror drug development arm, BARDA, has stepped up with a $94 million contract to support the development of a new gram-negative antibiotic in GlaxoSmithKline's ($GSK) pipeline. In-licensed from Anacor, GSK '052 now has ample R&D support over the next four years to back Phase II clinical trials for ventilator-associated pneumonia and Phase III trials for complicated intra-abdominal infections. "BARDA's financial support for the development of GSK '052 will help ensure the rapid development of this compound toward its approval in all relevant indications," said Anacor CEO David Perry. Release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.